Copanlisib and Avelumab as a Maintenance Therapy for Advanced Bladder Cancer
Status:
Not yet recruiting
Trial end date:
2026-12-31
Target enrollment:
Participant gender:
Summary
Patients with metastatic bladder cancer are usually treated with chemotherapy. If their
cancers do not progress after chemotherapy, they can be enrolled into this study and receive
a standard-of-care immunotherapy medication named avelumab plus a study drug named
copanlisib.